Methods: Equivalence was determined by developing a standard Forest plot that incorporated the information on margins previously reported in randomized trials on these agents. The end point was HbA 1c change from baseline; the equivalence margin was set at ±0.25% change in HbA 1c . The clinical material was obtained from a systematic review on this topic.
Results: Given as monotherapy, linagliptin, sitagliptin, and vildagliptin (but not saxagliptin) met the equivalence criterion when compared with one another. Given in combination with metformin, linagliptin, saxagliptin, sitagliptin, and vildagliptin showed an equivalent effect whereas alogliptin did not satisfy the equivalence criterion.
Conclusions: Considering the most recent therapeutic guidelines, our results are of interest particularly as regards the information on DPP-4 inhibitors in combination with metformin. Four of the five DPP-4 inhibitors under examination clearly showed to have the same effectiveness; the fifth agent-alogliptinfailed to meet the equivalence criterion, but only because its superiority could not be excluded. We have applied this approach to evaluate the equivalence of monotherapy with alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin versus placebo (Fig. 1a) and the equivalence of the same agents in combination with metformin versus metformin alone (Fig. 1b) . The end point was HbA 1c change from baseline. The equivalence margins were set at ±0.25% change in HbA 1c according to Buse et al. [7] . The clinical material that was reported by Craddy et al. [4] is presented in their Table 5 .
In our first analysis (Fig. 1a) , our equivalence testings found an equivalent treatment effect for linagliptin, sitagliptin, and vildagliptin given as monotherapy when compared with one another; the effect of saxagliptin did not satisfy the equivalence criterion, while the result for alogliptin was borderline. In our second analysis (Fig. 1b) , the combination of the same five agents in comparison with metformin alone showed an equivalent effect for linagliptin, saxagliptin sitagliptin, and vildagliptin whereas the combination including alogliptin did not satisfy the equivalence criterion.
It should be kept in mind that, in patients with type 2 diabetes, all international guidelines advocate metformin first. Hence, our analysis on monotherapy with DPP-4 inhibitors had more speculative than a practical interest. In contrast, the analysis evaluating the combination of DPP-4 inhibitors with metformin had some practical interest. In fact, four of the five DPP-4 inhibitors clearly showed to have the same effectiveness; the fifth agent-alogliptin-failed to meet the less important criterion of the ''left'' margin (so that its superiority cannot be excluded), but, however, fully satisfied the criterion of being non-inferior in comparison with the ''right'' margin. While the safety of these drugs is another important factor for defining their respective role in comparative terms, the evidence on this point seems to be more difficult to interpret because of the diversity of the safety end points and their relatively low frequency of occurrence [4] .
In conclusion, although our analyses have entirely been based on the same clinical material already published by Craddy et al. [4] , our results convey original information to better interpret the effectiveness of these agents in terms of equivalence. When . The equivalence test is applied based on the equivalence intervals that reflect the margins reported by Buse et al. [7] . The criterion for demonstrating equivalence (at alpha level = 2.5%) is when the entire 95% confidence interval remains within the equivalence interval. P values for equivalence were: a (top to bottom) 0.038, 0.024, 0.177, 0.002, 0.023; b (top to bottom) 0.103, 0.01, 0.003, 0.001, 0.002 treatment with a DPP-4 inhibitor in combination with metformin is started in a given patient, our findings indicate that the magnitude of the reduction in HbA 1c cannot represent the main criterion for selecting a specific agent in a given patient, since the expected improvement is essentially the same across these agents. Other criteria should, therefore, prevail, including the dosing schedule, the profile of adverse effects, and, last but not least, the cost.
